Comparison of Treatments for Uterine Cancer

What we are studying

The current standard management for patients with leiomyosarcoma of the uterus which has been completely removed by surgery is to follow patients closely to check if the leiomyosarcoma comes back. Many patients may remain without any evidence of the cancer coming back after having had surgery to take out the leiomyosarcoma. In some patients, however, the leiomyosarcoma does come back. Currently when leiomyosarcoma comes back (recurs) the leiomyosarcoma may be treated with chemotherapy. There are several chemotherapy drugs that can shrink leiomyosarcoma tumors. These include the combination treatment of gemcitabine and docetaxel, and another drug called doxorubicin. In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur). In this study half of the patients will be treated with chemotherapy and also followed to see if the disease comes back.

Who we are studying

  • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Confirmed diagnosis of high-risk uterine leiomyosarcoma

What is involved

  • Procedures depends on which part of the study you are assigned to.

Contact Information

Study Coordinator
Melissa Swain, RN
Email
mswain@wakehealth.edu
Phone
336-716-9428

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.